Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.


COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

January 30, 2024
Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical trials Participating investors include... Learn More

Lumira Ventures Portfolio Company enGene (Nasdaq: ENGN) Debuts as Publicly Traded Genetic Medicines Company

November 2, 2023
CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion Pivotal clinical trial for lead program EG-70 targeting... Learn More

Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia)

October 12, 2023
There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition. Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the... Learn More

OpSens, Inc Acquired by Haemonetics for $345 Million

October 10, 2023
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS)... Learn More

Team Lumira

Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.



Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.

  • "Lumira's philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael's ability to accelerate the pace."

    Dr. Arthur Slutsky | Vice-President
    Vice-President of Research at St. Michael's Hospital
  • "Lumira's model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation."

    Barbara Grantham | President & Ceo
    VGH & UBC Hospital Foundation
  • “This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”

    Paul Alofs | President & Ceo
    Princess Margaret Cancer Foundation

Contact Us

Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.



141 Adelaide Street
Suite 770
Toronto, ON
Canada, M5H 3L5



Espace CDPQ
3, Place Ville Marie
Bureau 12350, Niveau L
Montreal, QC
Canada, H3B 0E7



1021 West Hastings Street,
9th floor
Vancouver, BC
Canada, V6E 0C3



303 Wyman Street
Suite 300
Waltham, MA,
USA, 02451-1208